Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder

Phase

Condition

Borderline Personality Disorder

Suicide

Mood Disorders

Treatment

N/A

Clinical Study ID

NCT00834834

#5752/6777R

R01MH061017-06A2

R01MH061017

Ages 18-65
All Genders

Study Summary

This study will compare the effectiveness of two treatments, dialectical behavior therapy versus fluoxetine with clinical management, for reducing the risk of self-injury and suicidal behavior in people with borderline personality disorder.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Meets Diagnostic and Statistical Manual (DSM-IV) criteria for borderline personalitydisorder (BPD)
Attempted suicide in the past 2 months
At least one additional suicide attempt, suicide-related behavior, or self-injuryepisode in the past year
Current suicidal ideation
Able to be managed as an outpatient
Not currently receiving optimum psychiatric treatment and agrees to notify study staffif any psychiatric care outside this study is sought. If care other than thatpermitted by the protocol is utilized, participants can no longer be enrolled in thestudy.
Has a stable living arrangement at study entry
Speaks English
Willing and judged to be clinically able to undergo wash-out of psychotropicmedications, except for occasional benzodiazepines use, for 2 to 6 weeks beforetreatment
Females must be willing to use an effective method of birth control.

Exclusion

Exclusion Criteria:

Meets the DSM-IV criteria for mental retardation or the following disorders: bipolarI, schizophrenia, delusional disorder, schizophreniform disorder, schizoaffectivedisorder, or psychotic disorder not otherwise specified (NOS)
Needs priority treatment for acute medical illness or other debilitating problem, suchas severe substance dependence or anorexia
Pregnant
Clinically too unstable to be maintained as an outpatient
Has clearly failed adequate trials of fluoxetine and citalopram for a major depressionin the past 2 years
History of severe allergies, adverse drug reactions, or known allergy to fluoxetine orcitalopram
Clinically inadvisable for the participant to end current treatment
Heart pacemaker body implant; other metal implants, such as shrapnel or surgicalprostheses; or paramagnetic objects contained within the body, as assessed via a metalscreening questionnaire, which may present a risk to the participant or interfere withthe fMRI scan
Diagnosed with Raynaud's disorder
History of hypertension, cardiovascular disease, or abnormal electrocardiograms (EKGs)
Claustrophobia or significant discomfort in enclosed space

Study Design

March 01, 2009

August 31, 2015

Study Description

Borderline personality disorder (BPD) is a chronic disorder in emotional regulation and is characterized by instability in self-image, mood, relationships, and behavior. People suffering from BPD have a high rate of self-injury and suicide attempts. This study will compare the effectiveness of two treatments for preventing self-injury and suicide in people with BPD: dialectical behavior therapy (DBT) and fluoxetine with clinical management. DBT is a behavioral therapy that teaches new coping skills to replace old strategies, including self-injury and attempted suicide. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) medication that has been used to treat BPD. Clinical management of fluoxetine, which is involved in administering the medication under normal conditions, refers to regular visits with a psychiatrist who will monitor medication effectiveness and side effects. Clinical management in this study may include adjusting the dosage of fluoxetine or prescribing a change in medication to citalopram, another SSRI.

Participation in this study will last 12 months, including all follow-up assessments. During the first study visit, participants will undergo baseline testing and be randomly assigned to receive either DBT or fluoxetine with clinical management. After a washout period, in which participants will transition off any medications they are currently taking, participants will receive 6 months of their assigned treatment. Participants receiving DBT will attend one 60-minute individual therapy session and one 90-minute group session every week. Participants assigned to the fluoxetine with clinical management condition will begin receiving 20 mg of fluoxetine daily and have their dose increased over the course of 4 weeks, based on tolerance, up to 40 mg. Participants assigned to fluoxetine may also be switched to citalopram, if the study psychiatrist thinks it will be more effective. Participants assigned to either fluoxetine or citalopram will undergo monthly blood tests to monitor the level of medication in their bodies.

Every 2 weeks, participants will undergo assessments of treatment effectiveness and side effects. After 2, 4, 6, 9, and 12 months, participants will undergo various neuropsychological tests and clinical interviews and self-report questionnaires about mood and life experiences. At study entry and at Weeks 12 and 24, participants will use a handheld computer to complete a week-long assessment of emotions. Fully healthy female participants will be asked to complete a functional magnetic resonance imaging (fMRI) scan, which will assess their ability to regulate emotions at the neural level. The fMRI scan and a stress test (for both men and women) will be performed at baseline and after 6 months.

Connect with a study center

New York State Psychiatric Institute
New York, New York 10032
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.